Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as HS-20094
Olatorepatide · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Olatorepatide | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Olatorepatide arm 1 | EXPERIMENTAL | - |
| Olatorepatide arm 2 | EXPERIMENTAL | - |
| Olatorepatide arm 3 | EXPERIMENTAL | - |
| Olatorepatide arm 4 | EXPERIMENTAL | - |
| Olatorepatide arm 5 | EXPERIMENTAL | - |
| Matching Placebo arm 6 | ACTIVE_COMPARATOR | - |
| General Cohort | EXPERIMENTAL | - |
| Subgroup Cohort | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Olatorepatide | DRUG | Administered per the protocol |
| Placebo | DRUG | Administered per the protocol |
Key Inclusion Criteria: 1. Diagnosis of HS based on: 1. Documented or reported history of HS for ≥6 months prior to baseline visit 2. Confirmation of HS by the investigator during physical examination at screening 2. HS lesions present in at least 2 distinct anatomic areas as described in th...
Top 15 of 17 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Upadacitinib, Lutikizumab |
| Incyte Corporation | INCY | 6 | PHASE3 | povorcitinib, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 14 | PHASE3 | Remibrutinib, Secukinumab |
| Sanofi SA Sponsored ADR | SNY | 3 | PHASE2 | Duvakitug, Brivekimig, SAR445399 |
| MoonLake Immunotherapeutics Class A | MLTX | 2 | PHASE3 | Sonelokimab |
| Pfizer Inc. | PFE | 1 | PHASE2 | Ritlecitinib |
| Merck & Co., Inc. | MRK | 1 | PHASE2 | Tulisokibart |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Zasocitinib |
| Zura Bio Limited Class A | ZURA | 1 | PHASE2 | Tibulizumab |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | Olatorepatide |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY072 |
| Oruka Therapeutics, Inc. | ORKA | 1 | PHASE2 | ORKA-002 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE1 | SAR447971 |
| Evommune, Inc. | EVMN | 1 | EARLY_PHASE1 | EVO101 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE1 | Soquelitinib |
Olatorepatide is an investigational small molecule being developed by Regeneron Pharmaceuticals, Inc. (ticker: REGN) for hidradenitis suppurativa and for overweight or obesity. It is currently in Phase 2 clinical development and has not been approved by the FDA. It is designed to target MC4R.
Olatorepatide is being studied for two indications: moderate to severe hidradenitis suppurativa in adults living with overweight or obesity, and overweight or obesity in adults without diabetes. Both uses remain investigational, as the drug is in Phase 2 testing and has not received FDA approval for any indication.
Olatorepatide targets MC4R, the melanocortin 4 receptor. MC4R is a G protein-coupled receptor involved in energy balance and appetite regulation, making it a relevant pathway for weight-related conditions. Olatorepatide is a small molecule in the peptide-like class, and its activity at MC4R is the basis for its study in overweight or obesity and hidradenitis suppurativa.
Olatorepatide is being developed by Regeneron Pharmaceuticals, Inc., which trades under the ticker REGN. Regeneron is the sponsor of the Phase 2 clinical program evaluating the drug in hidradenitis suppurativa and in overweight or obesity.
Olatorepatide is in Phase 2 clinical development. It is investigational and has not been approved by the FDA. Two active Phase 2 trials are underway, and no completed trials have been reported. The program includes randomized, double-blind, placebo-controlled studies, with total planned enrollment of about 480 participants across the trials.
Olatorepatide is being evaluated in Phase 2 trials including NCT07830329 in moderate to severe hidradenitis suppurativa with overweight or obesity, NCT07685808 in overweight or obesity without diabetes in the United States, and NCT07431086 in overweight or obesity in the United States. These studies are randomized, double-blind, and placebo-controlled, enrolling adults aged 18 years and older.